14 dividend stocks that rose 100% or more in 5 years as the payouts doubled

In basketball, a double-double is a combination of at least 10 or more of the following in a game: points scored, rebounds, assists, blocked shots or steals. For dividend stocks, you might find a scre...

Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leadi...

Eli Lilly and Novo Stock Sold Off. Don’t Blame Their Diet Drugs.

Stock in Eli Lilly and Novo Nordisk outperformed last year, largely because of remarkable demand for new drugs that drive weight loss in patients afflicted with diabetes and obesity. Both stocks were ...

LLY Stock Dives After A ‘Bump In The Road’ Shakes Its Newest Diabetes Med

Eli Lilly (LLY) experienced a “bump in the road” for its newest diabetes treatment, Mounjaro, an analyst said Thursday as LLY stock toppled. X Mounjaro sales came out to $279.2 million, mi...

Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...

It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.

My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

ProQR’s stock jumps on expanded RNA deal with Lilly

Shares of ProQR Therapeutics NV PRQR, +73.03% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, -1.49% aimed at ma...

Nucor, CVS, and 11 More Companies That Raised Their Stock Dividends This Week

Eli Lilly Amgen Nucor and Franklin Resources were among the many companies that declared dividend increases this week. Eli Lilly (ticker: LLY) declared a quarterly payout of $1.13 a share, an increase...

Pfizer’s Earnings Are Tuesday. What to Watch.

Pfizer is set to report its earnings on Tuesday, a week and a half after an executive told investors that the company was considering a list price for its Covid-19 vaccine of between $110 and $130 per...

An Alzheimer’s Drug’s Big Surprise: What It Means

Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...

Buy Eli Lilly Stock. Its Obesity Drug Mounjaro Will Be a Hit, Analyst Says.

Text size Eli Lily said in August that initial demand for Mounjaro was strong. Daniel Acker/Bloomberg Eli Lilly’s novel treatment for diabetes and obesity could become one of history’s bestselling dru...

UBS upgrades Eli Lilly declaring LLY is working on ‘the biggest drug ever’

UBS Group (SWX: UBSG), a global financial provider, upgraded Eli Lilly (NYSE: LLY) to buy from neutral on Tuesday, September 20. UBS analyst Navin Jacob updated the price target from the previous $335...

Where Is the Stock Market Going? It Could Have a Messy Fall.

If 2022 were to end tomorrow, or the day after, it would enter the books as a dismal one for investors. The Dow Jones Industrial Average is down 13% year to date, the S&P 500 index is off 17%, and...

Uber, Boeing, Warner Bros. Discovery: Stocks That Defined the Week

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple ...

Novartis Will Cut 8,000 Jobs Under CEO’s Shake-Up Plan

Text size Vasant Narasimhan, CEO of Novartis. ERIC PIERMONT/AFP/Getty Images Pharmaceutical giant Novartis said Tuesday it will lay off more than 7% of its workforce, just a few months after CEO Vas N...

This dividend fund is down 3% vs. S&P’s 20% drop. Here are its top stock picks

By now even the most ardent tech and growth-stock enthusiasts realize the bull market is over. John Kornitzer’s approach to selecting high-quality stocks for the Buffalo Flexible Income Fund is one th...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...

Eli Lilly stock pulls back from record high after disclosing sales by largest shareholder

Shares of Eli Lilly & Co. LLY, -3.10% fell 4.0% in afternoon trading Tuesday, to pullback from the previous session’s record close, after the drug maker disclosed that its largest shareholde...

Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market

Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...

U.S. Stock Futures Poised for Lower Open on Monday

Stocks are poised to open lower on Monday. Michael Nagle/Bloomberg Text size Here’s what you need to know to navigate the markets today. • U.S. stocks are set to open Monday slightly down. On Sunday n...

Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug

Biogen Inc.’s BIIB, -8.92% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer’s disease drugs that includes the company’s th...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...